Add to ORKG1.1 Edoxaban is recommended, within its marketing authorisation, as an option for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors, including: congestive heart failure hypertension diabetes prior stroke or transient ischaemic attack age 75 years or older.https://www.nice.org.uk/guidance/ta35
We designed a prospective, randomized, open-label, blinded end point evaluation parallel group Phase...
Edoxaban recently proved non-inferior to warfarin for prevention of thromboembolism in patients with...
Stroke is one of the most serious cardiovascular events with severe consequences, up to paralysis an...
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant ...
edoxaban, warfarin, oral anticoagulation, atrial fibrillation, efficacy, safety.Introduction Oral an...
Marco Proietti,1,2 Gregory YH Lip1,3 1University of Birmingham Institute of Cardiovascular Sciences,...
Edoxaban, a reversible and direct inhibitor of factor Xa, is used to reduce the risk for stroke and ...
AIMS: Non-vitamin K oral anticoagulants are safe and effective for stroke prevention in patients wit...
Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and syste...
As non-valvular atrial fibrillation (AF) brings a risk of stroke, oral anticoagulants (OAC) are reco...
BACKGROUND: Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and syst...
BACKGROUND: Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and syst...
Summary Edoxaban is an oral, reversible, direct factor Xa inhibitor in phase III clinical developmen...
In the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-...
Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vi...
We designed a prospective, randomized, open-label, blinded end point evaluation parallel group Phase...
Edoxaban recently proved non-inferior to warfarin for prevention of thromboembolism in patients with...
Stroke is one of the most serious cardiovascular events with severe consequences, up to paralysis an...
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant ...
edoxaban, warfarin, oral anticoagulation, atrial fibrillation, efficacy, safety.Introduction Oral an...
Marco Proietti,1,2 Gregory YH Lip1,3 1University of Birmingham Institute of Cardiovascular Sciences,...
Edoxaban, a reversible and direct inhibitor of factor Xa, is used to reduce the risk for stroke and ...
AIMS: Non-vitamin K oral anticoagulants are safe and effective for stroke prevention in patients wit...
Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and syste...
As non-valvular atrial fibrillation (AF) brings a risk of stroke, oral anticoagulants (OAC) are reco...
BACKGROUND: Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and syst...
BACKGROUND: Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and syst...
Summary Edoxaban is an oral, reversible, direct factor Xa inhibitor in phase III clinical developmen...
In the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-...
Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vi...
We designed a prospective, randomized, open-label, blinded end point evaluation parallel group Phase...
Edoxaban recently proved non-inferior to warfarin for prevention of thromboembolism in patients with...
Stroke is one of the most serious cardiovascular events with severe consequences, up to paralysis an...